SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Lexeo Therapeutics Stock Climbs on Positive Interim Data for Heart-Disease Treatment

By Kelly CloonanShares of Lexeo Therapeutics gained on positive interim trial results for a treatment for a rare genetic heart disease.The stock climbed 24% to $3.55 in premarket trading on Monday. At Friday's market close, shares were down 71% year to date.Lexeo said interim data from an ongoing P…

LXEO

Related stories